Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 29 (Search time: 0.003 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2002
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation
Mullighan, C.
;
Heatley, S.
;
Doherty, K.
;
Szabo, F.
;
Grigg, A.
;
Hughes, T.
;
Schwarer, A.
;
Szer, J.
;
Tait, B.
;
To, L.
;
Bardy, P.
2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Grigg, A.
;
Arthur, C.
;
Taylor, K.
;
Herrmann, R.
;
Lynch, K.
;
Hughes, T.
1997
Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.
Hughes, T.
;
Grigg, A.
;
Szer, J.
;
Ho, J.
;
Ma, D.
;
Dale, B.
;
Green, R.
;
Norman, J.
;
Sage, R.
;
Herrmann, R.
;
Cannell, P.
;
Schwarer, A.
;
Taylor, K.
;
Atkinson, K.
;
Arthur, C.
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2000
Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen
Craddock, C.
;
Bardy, P.
;
Kreiter, S.
;
Johnston, R.
;
Apperley, J.
;
Marks, D.
;
Huber, C.
;
Kolbe, K.
;
Goulding, R.
;
Lawler, M.
;
Goldman, J.
;
Hughes, T.
;
Derigs, G.
2014
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
Nievergall, E.
;
Ramshaw, H.
;
Yong, A.
;
Biondo, M.
;
Busfield, S.
;
Vairo, G.
;
Lopez, A.
;
Hughes, T.
;
White, D.
;
Hiwase, D.
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
Discover
Author
12
White, D.
10
Branford, S.
8
Hochhaus, A.
7
Radich, J.
6
Grigg, A.
6
Kim, D.
5
Goldman, J.
5
Larson, R.
5
Saglio, G.
4
Arthur, C.
.
next >
Subject
29
Humans
28
Male
24
Adult
24
Middle Aged
22
Pyrimidines
20
Aged
20
Imatinib Mesylate
20
Piperazines
19
Benzamides
17
Leukemia, Myelogenous, Chronic, B...
.
next >
Date issued
14
2010 - 2018
14
2000 - 2009
1
1997 - 1999